2025-10-24 - Analysis Report
Okay, here's an analysis of Intuitive Surgical Inc. (ISRG) based on the data you provided. The report is structured to present key metrics upfront, followed by detailed analysis.

**Executive Summary**

Intuitive Surgical Inc. (ISRG) specializes in robotic-assisted surgical systems. While ISRG's cumulative return lags the S&P 500 (VOO) by approximately -30.9%, recent news and analyst ratings suggest a positive outlook. Recent earnings data is generally positive.

---

**1. Performance Relative to S&P 500 (VOO)**

*   **Ticker:** ISRG
*   **Company:** Intuitive Surgical Inc.
*   **Overview:** Develops and manufactures robotic surgical systems, most notably the da Vinci Surgical System.
*   **ISRG Cumulative Return:** 73.03%
*   **VOO Cumulative Return:** 99.09%
*   **Cumulative Return Difference (Lag):** -30.9%
*   **Relative Deviation:** 5.0

**Analysis:**

ISRG's cumulative return significantly trails behind the S&P 500. This suggests underperformance relative to the broader market index. The low Relative Deviation (5.0) indicates that the current lag is near the lowest end of its historical range, meaning the stock has rarely underperformed VOO by this much in the analyzed period.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha  | Beta | Cap(B) |
| :----------- | :------ | :----- | :----- | :--- | :------ |
| 2015-2017  | 70.0%   | 75.4%  | 41.0%  | 0.0  | 52.0   |
| 2016-2018  | 63.0%   | 72.3%  | 48.0%  | -0.0 | 68.2   |
| 2017-2019  | 53.0%   | 72.3%  | 31.0%  | 0.2  | 84.2   |
| 2018-2020  | -6.0%   | 80.6%  | -30.0% | 0.2  | 116.5  |
| 2019-2021  | 29.0%   | 80.6%  | -18.0% | 0.5  | 153.4  |
| 2020-2022  | -23.0%  | 80.6%  | -22.0% | 1.7  | 113.3  |
| 2021-2023  | -17.0%  | 77.4%  | -19.0% | 2.4  | 144.1  |
| 2022-2024  | 36.0%   | 77.4%  | 15.0%  | 2.5  | 222.9  |
| 2023-2025  | 35.0%   | 72.6%  | -29.0% | 0.8  | 197.6  |

**Analysis:**

*   **CAGR:** Varies significantly, showing periods of strong growth (70% in 2015-2017) and decline (-23% in 2020-2022).
*   **MDD:** Consistently high, indicating substantial drawdowns.
*   **Alpha:** Mostly negative in recent years, suggesting underperformance relative to the risk-free rate.
*   **Beta:** Increasing over time, implying greater sensitivity to market movements. High Beta may amplify the downside.
*   **Cap(B):** Increasing Capital Size.

**2. Recent Price Action**

*   **Current Price:** 462.74
*   **Last Market Data:** Price: 551.3, Previous Close: 527.03, Change: 4.61
*   **5-day Moving Average:** 447.51
*   **20-day Moving Average:** 442.97
*   **60-day Moving Average:** 458.49

**Analysis:**

The current price of 462.74 is above all moving averages. Recent market data indicates a significant increase in price (4.61), confirming upside momentum.

**3. Technical Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 64.02 (Approaching overbought territory but not yet there)
*   **PPO:** 0.7355 (Positive, indicating upward momentum)
*   **Hybrid Signal:** Buy 100% of cash
*   **Relative Deviation Change (20-day):** 2.0 (+), indicating short-term upward movement
*   **Expected Return:** 243.1% (Long-term, relative to S&P 500)

**Analysis:**

The MRI suggests that the stock is suitable for investment, with a high recommendation. The RSI indicates increasing buying pressure. The positive PPO confirms the upward momentum. The Hybrid Signal recommends buying. The significant price jump in the last market data further strengthens the short-term positive outlook. The high expected return suggests significant long-term potential relative to the S&P 500.

**4. Recent News & Significant Events**

*   **Earnings Live:** Mixed reactions for other companies (Intel, Ford, Deckers)
*   **Zacks:** "Buy the Post-Earnings Surge" suggests positive sentiment following earnings.
*   **UBS, Rothschild & Co Redburn, HSBC:** Price target adjustments upwards, with "Neutral" (UBS) and "Buy" ratings.

**Analysis:**

The news headlines are generally positive. Analysts are raising price targets, indicating confidence in the company's future performance. The Zacks article specifically recommends buying after the earnings surge.

**Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.94)
*   **Opinions:** 27
*   **Target Price:** Avg: 592.80 / High: 700.00 / Low: 378.00

**Analysis:**

The analyst consensus is a "Buy" with a mean rating of 1.94. The average target price of $592.80 suggests significant upside potential from the current price.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue |
| :----------- | :---- | :------- |
| 2025-10-22 | 1.98 | 2.51 B$ |
| 2025-07-23 | 1.84 | 2.44 B$ |
| 2025-04-23 | 1.95 | 2.25 B$ |
| 2024-10-18 | 1.59 | 2.04 B$ |
| 2025-10-22 | 1.59 | 2.04 B$ |

**Analysis:**

The recent earnings data shows increasing EPS and Revenue, which is a positive sign.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
| :---------- | :------- | :------------- |
| 2025-06-30 | $2.44B | 66.31%         |
| 2025-03-31 | $2.25B | 64.69%         |
| 2024-12-31 | $2.41B | 68.04%         |
| 2024-09-30 | $2.04B | 67.41%         |
| 2024-06-30 | $2.01B | 68.30%         |

**Capital and Profitability:**

| Quarter    | Equity    | ROE    |
| :---------- | :-------- | :----- |
| 2025-06-30 | $17.85B | 3.69% |
| 2025-03-31 | $17.11B | 4.08% |
| 2024-12-31 | $16.43B | 4.17% |
| 2024-09-30 | $15.58B | 3.63% |
| 2024-06-30 | $14.71B | 3.58% |

**Analysis:**

*   **Revenue:** Generally increasing, indicating growth.
*   **Profit Margin:** Consistently high, showing strong profitability.
*   **Equity:** Increasing, demonstrating a strengthening financial position.
*   **ROE:** Relatively stable, indicating consistent returns on equity.

**7. Overall Assessment**

Despite underperforming the S&P 500, Intuitive Surgical (ISRG) exhibits several positive indicators:

*   **Strong Financials:** Increasing revenue, high profit margins, and growing equity.
*   **Positive Momentum:** Recent price surge, positive PPO, and rising RSI.
*   **Analyst Confidence:** "Buy" consensus, rising price targets.
*   **High Expected Return:** Substantial long-term potential relative to the S&P 500.

**In summary, while past performance has lagged, recent developments suggest a potentially favorable outlook for ISRG.**
